The past several months have seen many successful merger and acquisition announcements come and go, but for some companies, this has hardly been a summer of love. Several of Big Pharma’s big offers have been rejected, and some of these stories are still playing out. Only time will tell what the future holds for these proposed deals and sometimes troubled partnerships. Read more »
The Japanese pharmaceutical company Daiichi Sankyo’s pending move to buy a controlling stake in the Indian pharmaceutical company Ranbaxy Laboratories for up to $4.6 billion took a rocky turn this week. Read more »
Covance’s (Princeton, NJ) announcement this week that it will partner with Shanghai’s WuxiPharmaTech in a joint venture for preclinical services reflects a shifting paradigm in pharmaceutical outsourcing. Read more »
The Japanese pharmaceutical company Daiichi Sankyo’s move this week to buy a controlling stake in the Indian pharmaceutical company Ranbaxy Laboratories for up to $4.6 billion is a pending marriage that reflects the rising importance of generic drugs, the growing role of emerging markets, and the need of innovator pharmaceutical companies to access lower cost R&D and manufacturing assets. Read more »
From PharmTech.com